Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Immunological Investigations|November 18, 2015
Active Immunotherapy of CancerThinle Chodon, Richard C Koya, Kunle OdunsiAdvances in Experimental Medicine and Biology|July 25, 2019
Cellular Immunotherapy in the Treatment of Hematopoietic MalignanciesSatoko Matsueda, Thinle Chodon, Richard C KoyaThe Journal of Investigative Dermatology|December 17, 2003
Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloidEmi Funayama, Thinle Chodon, Akihiko Oyama, et al.Hematology/Oncology Clinics of North America|November 5, 2018
Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian CancerThinle Chodon, Amit A Lugade, Sebastiano Battaglia, et al.Journal for Immunotherapy of Cancer|January 11, 2019
A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cellsJunko Matsuzaki, Takemasa Tsuji, Thinle Chodon, et al.Journal of Translational Medicine|May 22, 2009
CTLA4 blockade increases Th17 cells in patients with metastatic melanomaErika von Euw, Thinle Chodon, Narsis Attar, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapyPaul C Tumeh, Richard C Koya, Thinle Chodon, et al.Proceedings of the National Academy of Sciences of the United States of America|July 14, 2010
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responsesRichard C Koya, Stephen Mok, Begoña Comin-Anduix, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrationsBegoña Comin-Anduix, Thinle Chodon, Hooman Sazegar, et al.Cancer Immunology, Immunotherapy : CII|April 23, 2022
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destructionBrendan Zangari, Takemasa Tsuji, Junko Matsuzaki, et al.Pageof 4